Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)

Stefan Schreiber; Shomron Ben-Horin; Rieke Alten; René Westhovens; Laurent Peyrin-Biroulet; Silvio Danese; Toshifumi Hibi; Ken Takeuchi; Fernando Magro; Yoorim An; Dong Hyeon Kim; Sang Wook Yoon; Walter Reinisch

doi:10.1007/s12325-022-02082-9

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)

Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, René Westhovens, Laurent Peyrin-Biroulet, Silvio Danese, Toshifumi Hibi, Ken Takeuchi, Fernando Magro, Yoorim An, Dong Hyeon Kim, Sang Wook Yoon, Walter Reinisch^*

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Comment/debate

Abstract

In the original article, a few errors were by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made. The original article has been corrected.

Original language	English
Pages (from-to)	2281
Number of pages	1
Journal	Advances in Therapy
Volume	39
Issue number	5
DOIs	https://doi.org/10.1007/s12325-022-02082-9
State	Published - May 2022

Access to Document

10.1007/s12325-022-02082-9

Fingerprint

Dive into the research topics of 'Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)'. Together they form a unique fingerprint.

Cite this

Schreiber, S., Ben-Horin, S., Alten, R., Westhovens, R., Peyrin-Biroulet, L., Danese, S., Hibi, T., Takeuchi, K., Magro, F., An, Y., Kim, D. H., Yoon, S. W., & Reinisch, W. (2022). Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6). Advances in Therapy, 39(5), 2281. https://doi.org/10.1007/s12325-022-02082-9

@article{9a627f66bc11401a8f10bbd0eb9930b9,

title = "Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)",

abstract = "In the original article, a few errors were by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made. The original article has been corrected.",

author = "Stefan Schreiber and Shomron Ben-Horin and Rieke Alten and Ren{\'e} Westhovens and Laurent Peyrin-Biroulet and Silvio Danese and Toshifumi Hibi and Ken Takeuchi and Fernando Magro and Yoorim An and Kim, {Dong Hyeon} and Yoon, {Sang Wook} and Walter Reinisch",

note = "Publisher Copyright: {\textcopyright} Springer Healthcare Ltd., part of Springer Nature 2022ss.",

year = "2022",

month = may,

doi = "10.1007/s12325-022-02082-9",

language = "אנגלית",

volume = "39",

pages = "2281",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Springer International Publishing AG",

number = "5",

}

Schreiber, S, Ben-Horin, S, Alten, R, Westhovens, R, Peyrin-Biroulet, L, Danese, S, Hibi, T, Takeuchi, K, Magro, F, An, Y, Kim, DH, Yoon, SW & Reinisch, W 2022, 'Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)', Advances in Therapy, vol. 39, no. 5, pp. 2281. https://doi.org/10.1007/s12325-022-02082-9

Correction to : Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6). / Schreiber, Stefan; Ben-Horin, Shomron; Alten, Rieke et al.

In: Advances in Therapy, Vol. 39, No. 5, 05.2022, p. 2281.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)

AU - Schreiber, Stefan

AU - Ben-Horin, Shomron

AU - Alten, Rieke

AU - Westhovens, René

AU - Peyrin-Biroulet, Laurent

AU - Danese, Silvio

AU - Hibi, Toshifumi

AU - Takeuchi, Ken

AU - Magro, Fernando

AU - An, Yoorim

AU - Kim, Dong Hyeon

AU - Yoon, Sang Wook

AU - Reinisch, Walter

PY - 2022/5

Y1 - 2022/5

N2 - In the original article, a few errors were by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made. The original article has been corrected.

AB - In the original article, a few errors were by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85126190492&partnerID=8YFLogxK

U2 - 10.1007/s12325-022-02082-9

DO - 10.1007/s12325-022-02082-9

M3 - תגובה / דיון

C2 - 35287234

AN - SCOPUS:85126190492

VL - 39

SP - 2281

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 5

ER -

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this